Induction of Migraine Aura With Cilostazol

Completed

Phase 0 Results N/A

Trial Description

In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.

Detailed Description

Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.

Conditions

Interventions

  • Cilostazol (PletalĀ®)Drug
    Other Names: Claudiasil
    Intervention Desc: Single oral administration of active or placebo one week apart
    ARM 1: Kind: Experimental
    Label: Active
    Description: Cilostazol 200 mg single dose
  • Placebo Drug
    ARM 1: Kind: Experimental
    Label: Placebo
    Description: Placebo capsule

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Basic Science
  • Intervention: Crossover Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary Aura 24 hours No
Secondary Migraine 24 hours No
Secondary Endothelial response 3 hours No

Sponsors